Avalo Therapeutics, Inc.(AVTX)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,897 of 2,961 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
AVTX Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Avalo Therapeutics, Inc. (AVTX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores AVTX at 11.7/100 on a 32-signal composite quality model, placing it at rank #2,897 of 2,961 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue scale (0.2) and profitability (0.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 0.1/100, reflecting ongoing share issuance or stock-based compensation. Top institutional holders of AVTX by reported 13-F value include FMR, BlackRock, Deep Track Capital, based on the most recent SEC filings. AVTX trades on the Nasdaq exchange and files with the SEC under CIK 1534120. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AVTX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Avalo Therapeutics, Inc. directly from SEC EDGAR. Avalo Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 6 and 37 since 2025, currently 11.7 — an improving long-term trajectory across 52 quarterly and live scoring snapshots.
Net Income
Q2 2026
$-36.4M
ROIC
Q2 2026
-28.1%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
-86.6% YoYNet Income
-122.8% YoYOperating Income
-6.4% YoYEPS (Diluted)
+72.1% YoYTotal Assets
-22.7% YoYOp. Cash Flow
-4.9% YoYFree Cash Flow
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $59.0K -86.6% | $441.0K -77.1% | $1.9M -89.3% | $18.1M +234.4% | $5.4M -19.4% | $6.7M |
| Net Income | $-78.3M -122.8% | $-35.1M -11.4% | $-31.5M +24.3% | $-41.7M +50.6% | $-84.4M -32.9% | $-63.5M |
| Operating Income | $-72.9M -6.4% | $-68.5M -150.5% | $-27.4M +26.9% | $-37.4M +54.4% | $-82.1M -12.8% | $-72.8M |
| EPS (Diluted) | $-5.84 +72.1% | $-20.91 +81.6% | $-113.58 +89.3% | $-1063.00 | — | — |
| Total Assets | $116.5M -22.7% | $150.7M +618.0% | $21.0M -37.1% | $33.4M -58.4% | $80.2M +83.3% | $43.8M |
| Operating Cash Flow | $-51.5M -4.9% | $-49.1M -59.9% | $-30.7M -14.7% | $-26.8M +62.3% | $-70.9M -74.9% | $-40.5M |
| Free Cash Flow | — | — | — | $-26.8M +62.2% | $-71.0M -74.9% | $-40.6M |
Get alerted when AVTX's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Avalo Therapeutics, Inc. including:
Top Institutional Holders of AVTX
FMR LLC
$94.3M5,100,216 shBlackRock, Inc.
$80.7M4,365,553 shDeep Track Capital, LP
$66.7M3,610,000 shCaligan Partners LP
$58.5M3,163,866 shTCG Crossover Management, LLC
$55.8M3,017,120 shAffinity Asset Advisors, LLC
$53.6M2,900,000 shSTATE STREET CORP
$53.4M2,889,287 shFARALLON CAPITAL MANAGEMENT LLC
$46.2M2,498,000 shPoint72 Asset Management, L.P.
$44.1M2,387,026 shAvoro Capital Advisors LLC
$43.1M2,333,333 sh
| Fund | Value | Shares |
|---|---|---|
| FMR LLC | $94.3M | 5,100,216 |
| BlackRock, Inc. | $80.7M | 4,365,553 |
| Deep Track Capital, LP | $66.7M | 3,610,000 |
| Caligan Partners LP | $58.5M | 3,163,866 |
| TCG Crossover Management, LLC | $55.8M | 3,017,120 |
| Affinity Asset Advisors, LLC | $53.6M | 2,900,000 |
| STATE STREET CORP | $53.4M | 2,889,287 |
| FARALLON CAPITAL MANAGEMENT LLC | $46.2M | 2,498,000 |
| Point72 Asset Management, L.P. | $44.1M | 2,387,026 |
| Avoro Capital Advisors LLC | $43.1M | 2,333,333 |
Companies Similar to AVTX
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Xencor Inc
Taysha Gene Therapies, Inc.
Dianthus Therapeutics, Inc. /DE/
Nurix Therapeutics, Inc.
uniQure N.V.
PRECISION BIOSCIENCES INC
OCULAR THERAPEUTIX, INC
CRESCENT BIOPHARMA, INC.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put AVTX on your watchlist
Track score changes the day Avalo Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is AVTX a good stock to buy?
13F Pro's AI-powered analysis of Avalo Therapeutics, Inc. (AVTX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for AVTX are available on the AVTX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. AVTX is classified as a small company.
Which hedge funds own AVTX?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling AVTX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Avalo Therapeutics, Inc.'s investment landscape.